FDA probes severe hypocalcemia risk with Amgen’s osteoporosis drug

The FDA will investigate the risk of severe hypocalcemia that results in hospitalization and death with Amgen's osteoporosis drug, Prolia (denosumab). 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive